Filing Flows › Autolus Therapeutics (AUTL) › Q2 2026 › vs Q2 2025
Autolus Therapeutics (AUTL) Q2 2026 vs Q2 2025 (year over year)
Autolus Therapeutics's revenue rose $24.8M (+118%) from $20.9M in Q2 2025 to $45.7M in Q2 2026. The biggest changes: Product revenue, net +$24.7M (+118%); License revenue +$17K (—).
Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%, net loss $39.1M, operating cash flow −$25.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $45.7M | $20.9M | $24.7M | +118% |
| License revenue | $17K | $0 | $17K | — |
| Revenue | $45.7M | $20.9M | $24.8M | +118% |
| Other income, net | $5.2M | $13.7M | −$8.5M | -62% |
| Net loss | $39.1M | $47.9M | −$8.8M | -18% |
| Costs & expenses | $90.0M | $82.5M | $7.5M | +9% |
| Operating costs | $89.5M | $82.1M | $7.4M | +9% |
| Income tax | $465K | $397K | $68K | +17% |
| Cost of revenue | $20.5M | $24.4M | −$4.0M | -16% |
| Research & development | $27.9M | $27.4M | $468K | +2% |
| SG&A | $41.2M | $30.3M | $10.9M | +36% |
| Operating cash sources | $39.1M | $47.9M | −$8.8M | -18% |
| Depreciation & amortization | $2.2M | $2.1M | $78K | +4% |
| Share-based compensation | $4.6M | $4.3M | $302K | +7% |
| Working capital & other | $7.3M | −$31.2M | $38.5M | — |
| Cash used in operations | $25.1M | $72.8M | −$47.7M | -66% |
| Net loss absorbed | $39.1M | $47.9M | −$8.8M | -18% |
Questions
How much did Autolus Therapeutics's revenue grow year over year in Q2 2026?
Autolus Therapeutics's revenue rose $24.8M (+118%) from $20.9M in Q2 2025 to $45.7M in Q2 2026.
What drove Autolus Therapeutics's revenue change in Q2 2026?
Product revenue, net +$24.7M (+118%); License revenue +$17K (—).